J Tamaoki, M Kondo, N Sakai, J Nakata, H Takemura, A Nagai, T Takizawa and K Konno
First Department of Medicine, Tokyo Women's Medical College, Japan.

To test whether the leukotriene antagonist ONO-1078 (pranlukast) prevents asthma exacerbations during reduction of high-dose inhaled corticosteroid, we conducted a randomized, double-blind, placebo- controlled study in 79 asthma patients requiring high doses (1,500 microg/d or more) of inhaled beclomethasone dipropionate (BDI) for clinical control (duration of asthma, 11.0 +/- 3.1 yr; duration of BDI treatment, 0.5 +/- 0.3 yr; FEV1 percentage of predicted, 80.7 +/- 2.0%). After a 2-wk run-in period, the doses of BDI were halved, while the patients were assigned to receive orally ONO-1078, 450 mg twice daily, or placebo. In the placebo group FEV1 decreased by 0.33 +/- 0.20 L after 6 wk (p < 0.001). Likewise, morning and evening PEF decreased by 46 +/- 7 L/min and 18 +/- 6 L/min, respectively. By contrast these variables were sustained above baseline in the ONO-1078 group. The number of daytime and nighttime asthma symptoms and the use of beta2- agonist increased in the placebo group, whereas they remained unchanged in the ONO-1078 group. In the placebo group concentrations of serum eosinophil cationic protein and exhaled nitric oxide increased (p = 0.007 and p = 0.025, respectively), compared with no change in the ONO- 1078 group. Therefore, the leukotriene antagonist ONO-1078 prevents the asthma deterioration provoked by a 6-wk reduction of the dose of inhaled BDI into half.

This article has been cited by other articles:

				E. D. Bateman, S. S. Hurd, P. J. Barnes, J. Bousquet, J. M. Drazen, M. FitzGerald, P. Gibson, K. Ohta, P. O'Byrne, S. E. Pedersen, et al. Global strategy for asthma management and prevention: GINA executive summary Eur. Respir. J., January 1, 2008; 31(1): 143 - 178. [Abstract] [Full Text] [PDF]

				A. L. Fuhlbrigge, S. T. Weiss, K. M. Kuntz, A. D. Paltiel, and for the CAMP Research Group Forced Expiratory Volume in 1 Second Percentage Improves the Classification of Severity Among Children With Asthma Pediatrics, August 1, 2006; 118(2): e347 - e355. [Abstract] [Full Text] [PDF]

				W. A. Biernacki, S. A. Kharitonov, H. M. Biernacka, and P. J. Barnes Effect of Montelukast on Exhaled Leukotrienes and Quality of Life in Asthmatic Patients Chest, October 1, 2005; 128(4): 1958 - 1963. [Abstract] [Full Text] [PDF]

				G.P. Currie, P. Srivastava, O.J. Dempsey, and D.K.C. Lee Therapeutic modulation of allergic airways disease with leukotriene receptor antagonists QJM, March 1, 2005; 98(3): 171 - 182. [Abstract] [Full Text] [PDF]

				B. T. Kitch, A. D. Paltiel, K. M. Kuntz, D. W. Dockery, J. P. Schouten, S. T. Weiss, and A. L. Fuhlbrigge A Single Measure of FEV1 Is Associated With Risk of Asthma Attacks in Long-term Follow-up Chest, December 1, 2004; 126(6): 1875 - 1882. [Abstract] [Full Text] [PDF]

				P. M. O'Byrne Pharmacologic Interventions to Reduce the Risk of Asthma Exacerbations Proceedings of the ATS, April 1, 2004; 1(2): 105 - 108. [Abstract] [Full Text] [PDF]

				L. Prieto, L. Bruno, V. Gutierrez, S. Uixera, C. Perez-Frances, A. Lanuza, and A. Ferrer Airway Responsiveness to Adenosine 5'-Monophosphate and Exhaled Nitric Oxide Measurements: Predictive Value as Markers for Reducing the Dose of Inhaled Corticosteroids in Asthmatic Subjects Chest, October 1, 2003; 124(4): 1325 - 1333. [Abstract] [Full Text] [PDF]

				The ENFUMOSA Study Group The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma Eur. Respir. J., September 1, 2003; 22(3): 470 - 477. [Abstract] [Full Text] [PDF]

				B. B. Vargaftig and M. Singer Leukotrienes Mediate Murine Bronchopulmonary Hyperreactivity, Inflammation, and Part of Mucosal Metaplasia and Tissue Injury Induced by Recombinant Murine Interleukin-13 Am. J. Respir. Cell Mol. Biol., April 1, 2003; 28(4): 410 - 419. [Abstract] [Full Text] [PDF]

				S. O'Sullivan, M. Akveld, C. M. Burke, and L. W. Poulter Effect of the Addition of Montelukast to Inhaled Fluticasone Propionate on Airway Inflammation Am. J. Respir. Crit. Care Med., March 1, 2003; 167(5): 745 - 750. [Abstract] [Full Text] [PDF]

				F L M Ricciardolo Multiple roles of nitric oxide in the airways Thorax, February 1, 2003; 58(2): 175 - 182. [Abstract] [Full Text] [PDF]

				F. Kanniess, K. Richter, S. Janicki, M.B. Schleiss, R.A. Jorres, and H. Magnussen Dose reduction of inhaled corticosteroids under concomitant medication with montelukast in patients with asthma Eur. Respir. J., November 1, 2002; 20(5): 1080 - 1087. [Abstract] [Full Text] [PDF]

				T. Terashima, K. Amakawa, A. Matsumaru, and K. Yamaguchi Correlation Between Cysteinyl Leukotriene Release From Leukocytes and Clinical Response to a Leukotriene Inhibitor Chest, November 1, 2002; 122(5): 1566 - 1570. [Abstract] [Full Text] [PDF]

				F. Kanniess, K. Richter, S. Bohme, R.A. Jorres, and H. Magnussen Montelukast versus fluticasone: effects on lung function, airway responsiveness and inflammation in moderate asthma Eur. Respir. J., October 1, 2002; 20(4): 853 - 858. [Abstract] [Full Text] [PDF]

				O. J. Dempsey, S. J. Fowler, A. Wilson, G. Kennedy, and B. J. Lipworth Effects of Adding Either a Leukotriene Receptor Antagonist or Low-Dose Theophylline to a Low or Medium Dose of Inhaled Corticosteroid in Patients With Persistent Asthma* Chest, July 1, 2002; 122(1): 151 - 159. [Abstract] [Full Text] [PDF]

				F. M Ducharme Anti-leukotrienes as add-on therapy to inhaled glucocorticoids in patients with asthma: systematic review of current evidence BMJ, June 29, 2002; 324(7353): 1545 - 1545. [Abstract] [Full Text] [PDF]

				B. J. Lipworth and C. M. Jackson Bronchodilator Reversibility to Albuterol Predicts Bronchodilator Response to Salmeterol Chest, April 1, 2002; 121(4): 1382 - 1382. [Full Text] [PDF]

				K. Minoguchi, Y. Kohno, H. Minoguchi, N. Kihara, Y. Sano, H. Yasuhara, and M. Adachi Reduction of Eosinophilic Inflammation in the Airways of Patients With Asthma Using Montelukast Chest, March 1, 2002; 121(3): 732 - 738. [Abstract] [Full Text] [PDF]

				S.-E. DAHLEN, K. MALMSTROM, E. NIZANKOWSKA, B. DAHLEN, P. KUNA, M. KOWALSKI, W. R. LUMRY, C. PICADO, D. D. STEVENSON, J. BOUSQUET, et al. Improvement of Aspirin-Intolerant Asthma by Montelukast, a Leukotriene Antagonist . A Randomized, Double-Blind, Placebo-Controlled Trial Am. J. Respir. Crit. Care Med., January 1, 2002; 165(1): 9 - 14. [Abstract] [Full Text] [PDF]

				S. S. Salvi, M. T. Krishna, A. P. Sampson, and S. T. Holgate The Anti-inflammatory Effects of Leukotriene-Modifying Drugs and Their Use in Asthma Chest, May 1, 2001; 119(5): 1533 - 1546. [Abstract] [Full Text] [PDF]

				A. M. Wilson, O. J. Dempsey, E. J. Sims, and B. J. Lipworth Evaluation of Salmeterol or Montelukast as Second-Line Therapy for Asthma Not Controlled With Inhaled Corticosteroids Chest, April 1, 2001; 119(4): 1021 - 1026. [Abstract] [Full Text] [PDF]

				M. Eccles, N. Rousseau, B. Higgins, and L. Thomas Evidence-based guideline on the primary care management of asthma Fam. Pract., April 1, 2001; 18(2): 223 - 229. [Full Text] [PDF]

				H. Bisgaard Leukotriene Modifiers in Pediatric Asthma Management Pediatrics, February 1, 2001; 107(2): 381 - 390. [Abstract] [Full Text]

				O J Dempsey Leukotriene receptor antagonist therapy Postgrad. Med. J., December 1, 2000; 76(902): 767 - 773. [Abstract] [Full Text]

				A. DEYKIN, O. BELOSTOTSKY, C. HONG, A. F. MASSARO, C. M. LILLY, and E. ISRAEL Exhaled Nitric Oxide following Leukotriene E4 and Methacholine Inhalation in Patients with Asthma Am. J. Respir. Crit. Care Med., November 1, 2000; 162(5): 1685 - 1689. [Abstract] [Full Text]

				A. M. WILSON, L. C. ORR, E. J. SIMS, O. J. DEMPSEY, and B. J. LIPWORTH Antiasthmatic Effects of Mediator Blockade versus Topical Corticosteroids in Allergic Rhinitis and Asthma Am. J. Respir. Crit. Care Med., October 1, 2000; 162(4): 1297 - 1301. [Abstract] [Full Text] [PDF]

				J. CHRISTIAN VIRCHOW Jr., A. PRASSE, I. NAYA, L. SUMMERTON, A. HARRIS, and The Zafirlukast Study Group Zafirlukast Improves Asthma Control in Patients Receiving High-Dose Inhaled Corticosteroids Am. J. Respir. Crit. Care Med., August 1, 2000; 162(2): 578 - 585. [Abstract] [Full Text] [PDF]

				E. LEE, T. ROBERTSON, J. SMITH, and S. KILFEATHER Leukotriene Receptor Antagonists and Synthesis Inhibitors Reverse Survival in Eosinophils of Asthmatic Individuals Am. J. Respir. Crit. Care Med., June 1, 2000; 161(6): 1881 - 1886. [Abstract] [Full Text]

				J. BOUSQUET, P. K. JEFFERY, W. W. BUSSE, M. JOHNSON, and A. M. VIGNOLA Asthma . From Bronchoconstriction to Airways Inflammation and Remodeling Am. J. Respir. Crit. Care Med., May 1, 2000; 161(5): 1720 - 1745. [Full Text]

				B. DAHLEN Treatment of Aspirin-intolerant Asthma with Antileukotrienes Am. J. Respir. Crit. Care Med., February 1, 2000; 161(2): S137 - 141. [Full Text] [PDF]

				A. JATAKANON, S. LIM, and P. J. BARNES Changes in Sputum Eosinophils Predict Loss of Asthma Control Am. J. Respir. Crit. Care Med., January 1, 2000; 161(1): 64 - 72. [Abstract] [Full Text]

				M. LAVIOLETTE, K. MALMSTROM, S. LU, P. CHERVINSKY, J.-C. PUJET, I. PESZEK, J. ZHANG, and T. F. REISS Montelukast Added to Inhaled Beclomethasone in Treatment of Asthma Am. J. Respir. Crit. Care Med., December 1, 1999; 160(6): 1862 - 1868. [Abstract] [Full Text]

				T. Casale Immunobiology of Asthma and Rhinitis . Pathogenic Factors and Therapeutic Options Am. J. Respir. Crit. Care Med., November 1, 1999; 160(5): 1778 - 1787. [Full Text]

				Leukotriene-receptor antagonists and related compounds Can. Med. Assoc. J., November 1, 1999; 161(90111): s31 - 34. [Full Text]

				S. M. Harding The Dull-Edged Sword of Inhaled Corticosteroids Chest, October 1, 1999; 116(4): 854 - 856. [Full Text] [PDF]

				H. BISGAARD, L. LOLAND, and J. A. ØJ NO in Exhaled Air of Asthmatic Children Is Reduced by the Leukotriene Receptor Antagonist Montelukast Am. J. Respir. Crit. Care Med., October 1, 1999; 160(4): 1227 - 1231. [Abstract] [Full Text]

				H. M. Sarau, R. S. Ames, J. Chambers, C. Ellis, N. Elshourbagy, J. J. Foley, D. B. Schmidt, R. M. Muccitelli, O. Jenkins, P. R. Murdock, et al. ACCELERATED COMMUNICATION: Identification, Molecular Cloning, Expression, and Characterization of a Cysteinyl Leukotriene Receptor Mol. Pharmacol., September 1, 1999; 56(3): 657 - 663. [Abstract] [Full Text]

				C.-G. Löfdahl, T. F Reiss, J. A Leff, E. Israel, M. J Noonan, A. F Finn, B. C Seidenberg, T. Capizzi, S. Kundu, and P. Godard Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients BMJ, July 10, 1999; 319(7202): 87 - 90. [Abstract] [Full Text]

				A. S. Go and S. E. Wenzel Evidence Supporting Antileukotriene Agents for Asthma JAMA, May 12, 1999; 281(18): 1694 - 1694. [Full Text] [PDF]

				J. M. Drazen, E. Israel, and P. M. O'Byrne Treatment of Asthma with Drugs Modifying the Leukotriene Pathway N. Engl. J. Med., January 21, 1999; 340(3): 197 - 206. [Full Text] [PDF]

				S. E. Wenzel Antileukotriene Drugs in the Management of Asthma JAMA, December 23, 1998; 280(24): 2068 - 2069. [Full Text] [PDF]

				E. Sato, S. Koyama, Y. Okubo, K. Kubo, and M. Sekiguchi Acetylcholine stimulates alveolar macrophages to release inflammatory cell chemotactic activity Am J Physiol Lung Cell Mol Physiol, June 1, 1998; 274(6): L970 - L979. [Abstract] [Full Text] [PDF]

				B. DAHLEN, E. NIZANKOWSKA, A. SZCZEKLIK, O. ZETTERSTROM, G. BOCHENEK, M. KUMLIN, L. MASTALERZ, G. PINIS, L. J. SWANSON, T. I. BOODHOO, et al. Benefits from Adding the 5-Lipoxygenase Inhibitor Zileuton to Conventional Therapy in Aspirin-intolerant Asthmatics Am. J. Respir. Crit. Care Med., April 1, 1998; 157(4): 1187 - 1194. [Abstract] [Full Text] [PDF]

				R. J. HORWITZ, K. A. MCGILL, and W. W. BUSSE The Role of Leukotriene Modifiers in the Treatment of Asthma Am. J. Respir. Crit. Care Med., May 1, 1997; 157(5): 1363 - 1371. [Full Text]